{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T16:10:02Z","timestamp":1750695002509,"version":"3.41.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"This study was funded by Hexal AG, a Sandoz company."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40268-025-00507-8","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T03:06:47Z","timestamp":1745550407000},"page":"107-115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis Treated with GP2015, an Etanercept Biosimilar: Results from Two Phase III Studies (EGALITY and EQUIRA)"],"prefix":"10.1007","volume":"25","author":[{"given":"Diamant","family":"Tha\u00e7i","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6667-7757","authenticated-orcid":false,"given":"Sascha","family":"Gerdes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Both","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreekanth","family":"Gattu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohaib","family":"Hachaichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"issue":"13 Suppl","key":"507_CR1","first-page":"S295","volume":"18","author":"A Gibofsky","year":"2012","unstructured":"Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care. 2012;18(13 Suppl):S295\u2013302.","journal-title":"Am J Manag Care"},{"issue":"1","key":"507_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","volume":"3","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Rheumatol Ther. 2016;3(1):91\u2013102.","journal-title":"Rheumatol Ther"},{"issue":"4","key":"507_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1586\/14737167.2014.914437","volume":"14","author":"M Augustin","year":"2014","unstructured":"Augustin M, Radtke MA. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Res. 2014;14(4):559\u201368.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"unstructured":"US Food and Drug Administration: Remicade\u00ae (infliximab) [Prescribing Information] In: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/103772s5359lbl.pdf. Horsham, PA: Janssen Biotech, Inc.; Accessed 31 Mar 2025.","key":"507_CR4"},{"unstructured":"US Food and Drug Administration: Enbrel\u00ae (etanercept) [Prescribing Information] In: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103795s5503lbl.pdf. Thousand Oaks, CA: Immunex Corporation; Accessed 31 Mar 2025.","key":"507_CR5"},{"unstructured":"US Food and Drug Administration: Humira\u00ae (adalimumab) [Prescribing Information] In: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/125057s0110lbl.pdf. North Chicago, IL: AbbVie Inc.; Accessed 31 Mar 2025.","key":"507_CR6"},{"issue":"3","key":"507_CR7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1136\/annrheumdis-2012-202715","volume":"72","author":"T D\u00f6rner","year":"2013","unstructured":"D\u00f6rner T, Strand V, Casta\u00f1eda-Hern\u00e1ndez G, Ferraccioli G, Isaacs JD, Kvien TK, Martin-Mola E, Mittendorf T, Smolen JS, Burmester GR. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 2013;72(3):322\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"507_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.blre.2014.08.003","volume":"28","author":"BR Hirsch","year":"2014","unstructured":"Hirsch BR, Lyman GH. Biosimilars: a cure to the U.S. health care cost conundrum? Blood Rev. 2014;28(6):263\u20138.","journal-title":"Blood Rev"},{"issue":"9","key":"507_CR9","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/ard-2022-223696","volume":"82","author":"M Stajszczyk","year":"2023","unstructured":"Stajszczyk M, Obarska I, Jeka S, Batko B. Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database. Ann Rheum Dis. 2023;82(9):1171\u201380.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"507_CR10","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1080\/14712598.2023.2273938","volume":"23","author":"GL Goll","year":"2023","unstructured":"Goll GL, Kvien TK. Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway. Expert Opin Biol Ther. 2023;23(12):1203\u20139.","journal-title":"Expert Opin Biol Ther"},{"doi-asserted-by":"crossref","unstructured":"Stajszczyk M, Kwiatkowska B, Zuber ZM, Batko B. Access to biologics and Janus kinase inhibitors for treatment of rheumatic diseases in the biosimilars era in Poland: a nation-level study. Pol Arch Intern Med. 2024;134(4):16655. https:\/\/pubmed.ncbi.nlm.nih.gov\/38165391\/","key":"507_CR11","DOI":"10.20452\/pamw.16655"},{"issue":"1","key":"507_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40259-020-00456-5","volume":"35","author":"E Moorkens","year":"2021","unstructured":"Moorkens E, Vulto AG, Kent J, McClure L, Boldero R, Vanhove T, Simoens S, Huys I. A look at the history of biosimilar adoption: characteristics of early and late adopters of infliximab and etanercept biosimilars in subregions of England, Scotland and Wales\u2014a mixed methods study. BioDrugs. 2021;35(1):75\u201387.","journal-title":"BioDrugs"},{"unstructured":"US Food and Drug Administration: Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. In: https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm291128.pdf. Accessed 31 Mar 2025.","key":"507_CR13"},{"issue":"1","key":"507_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000019","volume":"1","author":"L Gossec","year":"2015","unstructured":"Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1(1):e000019.","journal-title":"RMD Open"},{"issue":"10","key":"507_CR15","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1001\/jamadermatol.2021.3341","volume":"157","author":"JS Barbieri","year":"2021","unstructured":"Barbieri JS, Gelfand JM. Patient-reported outcome measures as complementary information to clinician-reported outcome measures in patients with psoriasis. JAMA Dermatol. 2021;157(10):1236\u20137.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"507_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.rdc.2016.01.002","volume":"42","author":"AM Orbai","year":"2016","unstructured":"Orbai AM, Ogdie A. Patient-reported outcomes in psoriatic arthritis. Rheum Dis Clin North Am. 2016;42(2):265\u201383.","journal-title":"Rheum Dis Clin North Am"},{"key":"507_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/PROM.S256715","volume":"13","author":"G Horta-Baas","year":"2022","unstructured":"Horta-Baas G. Patient-reported outcomes in rheumatoid arthritis: a key consideration for evaluating biosimilar uptake? Patient Relat Outcome Meas. 2022;13:79\u201395.","journal-title":"Patient Relat Outcome Meas"},{"issue":"1","key":"507_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000232","volume":"2","author":"R Fleischmann","year":"2016","unstructured":"Fleischmann R, Strand V, Wilkinson B, Kwok K, Bananis E. Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-na\u00efve patients with rheumatoid arthritis. RMD Open. 2016;2(1):e000232.","journal-title":"RMD Open"},{"key":"507_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/PROM.S156279","volume":"9","author":"R Mercieca-Bebber","year":"2018","unstructured":"Mercieca-Bebber R, King MT, Calvert MJ, Stockler MR, Friedlander M. The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Relat Outcome Meas. 2018;9:353\u201367.","journal-title":"Patient Relat Outcome Meas"},{"unstructured":"US Food and Drug Administration: Erelzi (etanercept) [Prescribing Information] In: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761042lbl.pdf. Accessed 31 Mar 2025.","key":"507_CR20"},{"unstructured":"European Medicines Agency: Erelzi (etanercept) [Summary of Product Characteristics] In: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/erelzi. Accessed 31 Mar 2025.","key":"507_CR21"},{"issue":"4","key":"507_CR22","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/bjd.15152","volume":"176","author":"CEM Griffiths","year":"2017","unstructured":"Griffiths CEM, Tha\u00e7i D, Gerdes S, Arenberger P, Pulka G, Kingo K, Weglowska J, Hattebuhr N, Poetzl J, Woehling H, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176(4):928\u201338.","journal-title":"Br J Dermatol"},{"issue":"2","key":"507_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000757","volume":"4","author":"M Matucci-Cerinic","year":"2018","unstructured":"Matucci-Cerinic M, Allanore Y, Kavanaugh A, Buch MH, Schulze-Koops H, Kucharz EJ, Woehling H, Babic G, Poetzl J, Davis A, et al. Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. RMD Open. 2018;4(2):e000757.","journal-title":"RMD Open"},{"issue":"1","key":"507_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13075-019-1907-x","volume":"21","author":"J Jaworski","year":"2019","unstructured":"Jaworski J, Matucci-Cerinic M, Schulze-Koops H, Buch MH, Kucharz EJ, Allanore Y, Kavanaugh A, Young P, Babic G. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Arthritis Res Ther. 2019;21(1):130.","journal-title":"Arthritis Res Ther"},{"issue":"20","key":"507_CR25","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"issue":"3","key":"507_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/jdv.14605","volume":"32","author":"S Gerdes","year":"2018","unstructured":"Gerdes S, Tha\u00e7i D, Griffiths CEM, Arenberger P, Poetzl J, Wuerth G, Afonso M, Woehling H. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. J Eur Acad Dermatol Venereol. 2018;32(3):420\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"507_CR27","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/jdv.12934","volume":"29","author":"KA Papp","year":"2015","unstructured":"Papp KA, Barber K, Bissonnette R, Bourcier M, Lynde CW, Poulin Y, Shelton J, Garces K, Toole J, Poulin-Costello M. Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE. J Eur Acad Dermatol Venereol. 2015;29(8):1555\u201361.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"507_CR28","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/09546634.2019.1606886","volume":"31","author":"C Bonifati","year":"2020","unstructured":"Bonifati C, De Felice C, Lora V, Morrone A, Graceffa D. Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study. J Dermatolog Treat. 2020;31(7):687\u201391.","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"507_CR29","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1136\/annrheumdis-2017-211591","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery P, Vencovsk\u00fd J, Sylwestrzak A, Leszczy\u0144ski P, Porawska W, Stasiuk B, Hilt J, Mosterova Z, Cheong SY, Ghil J. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis. 2017;76(12):1986\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"507_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2015-207613","volume":"76","author":"SC Bae","year":"2017","unstructured":"Bae SC, Kim J, Choe JY, Park W, Lee SH, Park YB, Shim SC, Lee SS, Sung YK, Choi CB, et al. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. Ann Rheum Dis. 2017;76(1):65\u201371.","journal-title":"Ann Rheum Dis"},{"key":"507_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f167","volume":"346","author":"N Black","year":"2013","unstructured":"Black N. Patient reported outcome measures could help transform healthcare. BMJ. 2013;346:f167.","journal-title":"BMJ"},{"issue":"2","key":"507_CR32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/HMR.0b013e318208cd31","volume":"36","author":"C Rathert","year":"2011","unstructured":"Rathert C, Huddleston N, Pak Y. Acute care patients discuss the patient role in patient safety. Health Care Manage Rev. 2011;36(2):134\u201344.","journal-title":"Health Care Manage Rev"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00507-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-025-00507-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00507-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:55:15Z","timestamp":1750694115000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-025-00507-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["507"],"URL":"https:\/\/doi.org\/10.1007\/s40268-025-00507-8","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"16 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Hexal AG, a Sandoz company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Diamant Tha\u00e7i declares having attended advisory boards and\/or received consultancy fees and\/or received grants as an investigator from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen-Cilag, LEO Pharma, New Bridge, Novartis, Pfizer, Regeneron Pharmaceuticals, Samsung, Sandoz, Sanofi, Sun Pharmaceutical Industries, and UCB\u00a0Pharma. Sascha Gerdes has been an advisor and\/or received speakers\u2019 honoraria and\/or received grants and\/or participated in clinical trials for the following companies: AbbVie, Affibody AB, Akari Therapeutics Plc, Almirall-Hermal, Amgen, Anaptys Bio, Argenx BV, AstraZeneca AB, Biogen Idec, Bioskin,  Boehringer\u00a0Ingelheim, Bristol Myers Squibb,\u00a0Celgene, Dermira, Eli Lilly, Foamix, Forward Pharma, Galderma, Hexal AG, Incyte Inc., Janssen-Cilag, Johnson & Johnson, Klinge Pharma, Kymab, Leo Pharma, Medac, MSD, Neubourg Skin Care GmbH, Novartis, Pfizer, Principia Biopharma, Regeneron Pharmaceuticals, Sandoz Biopharmaceuticals, Sanofi-Aventis, Trevi Therapeutics, and UCB Pharma. Hendrik Schulze-Koops receives honoraria for lectures and consultations from AbbVie, Amgen, AstraZeneca, Biogen International, Bristol\u00a0Myers\u00a0Squibb, Boehringer Ingelheim, Celgene, Celltrion, Gilead, GSK, Hexal Sandoz,\u00a0Hospira, Janssen-Cilag, Lilly, Medac, Merck, MSD,\u00a0Mundipharma, Mylan, Novartis, Pfizer, Roche,\u00a0Sanofi-Aventis, and UCB Pharma. Yannick Allanore reports personal fees from Sandoz, and grants and personal fees from Pfizer and Roche, during the conduct of the study. Arthur Kavanaugh has received honoraria for lectures and consultations from AbbVie, Amgen, Eli Lilly,\u00a0Janssen, Novartis, Pfizer, and UCB Pharma. Charlotte Both is a former employee of Sandoz. Sreekanth Gattu is an employee of Sandoz. Sohaib Hachaichi is a former employee of Sandoz. Marco Matucci-Cerinic has received fees for participation in review activities such as data monitoring boards, etc. from Biogen and\u00a0speaker bureau fees\u00a0from Boehringer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The two studies (EGALITY and EQUIRA) were conducted in accordance with the ethical principles derived from the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practices and in compliance with local regulatory requirements. The study protocols were approved by the Independent Ethics Committee or Institutional Review Board for each center. The details of the Independent Ethics Committees and Institutional Review Boards for both studies are provided in the Supplementary information (ESM).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All patients provided written informed consent before entering the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All patients provided their consent for their data to be published.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data generated or analyzed in relation to PROs are included in this article and the supplementary information files. Anonymized datasets and related documents, such as the statistical analysis plan, protocol, and amendments, can be shared upon reasonable request to the corresponding author through a data sharing agreement.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Diamant Tha\u00e7i contributed to the design and\u00a0conduct of the clinical studies, and\u00a0the analysis and interpretation of the results, discussed the results, and contributed to the manuscript; Sascha Gerdes contributed to the conduct of the clinical studies, discussed the results, and contributed to the manuscript; Hendrik Schulze-Koops contributed to the conduct of the clinical studies, and\u00a0the analysis and interpretation of the results, discussed the results, and contributed to the manuscript; Yannick Allanore, Arthur Kavanaugh, Charlotte Both, Sreekanth Gattu, Sohaib Hachaichi, and Marco Matucci-Cerinic contributed to the interpretation of the results, discussed the results, and contributed to the manuscript. All authors have read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}